Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHAMROCK study of neoadjuvant trastuzumab deruxtecan with response-directed therapy in early HER2-positive breast cancer
2024-516582-36-00Phase 3Authorised
- Sponsor
- Cancer Trials Ireland
- Start
- Sep 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of trastuzumab deruxtecan in breast cancer, sponsored by Cancer Trials Ireland. Primary endpoint: Imaging complete response after 4 cycles of trastuzumab deruxtecan. Planned start Sep 2024; status: authorised.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-516582-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516582-36-00.